Zydus Receives USFDA EIR for Baddi Facility
Zydus Lifesciences has announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drugs Administration (USFDA) for its manufacturing facility in Baddi.
The inspection, which took place from August 4th to 13th, 2025, resulted in four observations, and the EIR has classified the facility as Voluntary Action Indicated (VAI).
The USFDA has concluded the inspection as closed.
Zydus Lifesciences Ltd. is a global lifesciences company that discovers, develops, manufactures, and markets a range of healthcare therapies.
No additional information is available.
Author's summary: Zydus receives USFDA EIR report.
More News
- Baxter stock slides as Q3 sales come up short, guidance lowered
- Why Israel Lost the Gaza Opinion War
- Trump Goes Full Dictator With Bonkers Threat to Use Air Force and Navy in U.S. Cities
- Eala falls to Mboko to exit Hong Kong Open
- Chipotle’s Stock Plunges 18% On Lowered Guidance
- Best early Black Friday deals 2025: 40+ sales out early
- Emmy-Winner Chronicles Yankees Icon Joe Torre’s MLB Legacy On Screen
- Integra stock dips on lowered guidance after Q3 sales miss
- A pyrrhic budget victory could land Carney in the legislative hurt…
- Familial Clustering Identified in Primary Hyperparathyroidism